Aurinia Pharmaceuticals announced that ICER (the Institute for Clinical and Economic Review) has released a positive Evidence Report for its LUPKYNIS (voclosporin) drug. This drug is a significant improvement over the current standard of care for lupus nephritis. In addition, ICER noted that LUPKYNIS might reduce historic disparities.
According to Aurinia CEO Peter Greenleaf, “We are encouraged by ICER’s recognition of the burden of lupus nephritis, particularly its impact on the racial disparities that we know exist. ICER’s assessment of LUPKYNIS is consistent with the real-world view of LUPKYNIS’ value we are hearing during our positive interactions with both physicians and payers during the first two months since our launch,” adding, “As we observed in our clinical studies, patients responded to voclosporin nearly two times faster than the current standard of care within one year and we are confident that with this time-to-response and efficacy data, LUPKYNIS provides significant therapeutic and economic value for patients and the healthcare system.” Read more here.
(Source: Aurinia Pharma, 3/15/21)